SLNO Insider Trading Activity and SEC Form 4 Filings
SLNO insider trading summary
Over the past 12 months, insiders at Soleno Therapeutics Inc (SLNO) reported 6 sales worth $429K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $429K.
Latest SLNO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 27, 2026 | Meredith Manning | Chief Commercial Officer | Sell | $146K (4,864 @ $30.04) |
| Mar 27, 2026 | Michael F. Huang | Sr. VP of Clinical Development | Sell | $15K (488 @ $31.72) |
| Mar 27, 2026 | Meredith Manning | Chief Commercial Officer | Sell | $18K (558 @ $31.72) |
| Mar 27, 2026 | Meredith Manning | Chief Commercial Officer | Sell | $65K (2,100 @ $31.04) |
| Mar 27, 2026 | Michael F. Huang | Sr. VP of Clinical Development | Sell | $128K (4,256 @ $30.04) |
| Mar 27, 2026 | Michael F. Huang | Sr. VP of Clinical Development | Sell | $57K (1,838 @ $31.04) |
| Jul 1, 2025 | Patricia C Hirano | See Remarks | Sell | $317K (3,830 @ $82.76) |
| Jun 24, 2025 | Patricia C Hirano | See Remarks | Sell | $22K (266 @ $84.25) |
| Apr 1, 2025 | Patricia C Hirano | See Remarks | Sell | $265K (3,782 @ $70.11) |
| Mar 28, 2025 | Patricia C Hirano | See Remarks | Sell | $198K (2,691 @ $73.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.